{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:15:49Z","timestamp":1791314149020,"version":"4.3.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Data"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Prostate cancer is a heterogeneous disease showing variability both among individuals and within a patient. While most cases are indolent, aggressive tumors require early intervention. Accurately predicting tumor behavior is challenging, contributing to overdiagnosis but also undertreatment. Current imaging methods may miss the most malignant areas, leading to biopsies often capturing non-malignant prostate tissue even if cancer is present elsewhere in the organ. This non-malignant tissue, however, holds potential as a source for novel diagnostic and prognostic markers. Our clinical dataset comprises men with raised prostate-specific antigen but whose initial prostate needle biopsies only contained benign tissue. Half of the paired patients remained cancer-free for over eight years, while the others were diagnosed with prostate cancer within 30 months of follow-up. We share these initial benign biopsies to enable the exploration of morphological changes in non-malignant tissue and the potential for improved diagnostic accuracy in the early identification of patients with prostate cancer.<\/jats:p>","DOI":"10.1038\/s41597-025-04758-7","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T11:21:02Z","timestamp":1741692062000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A clinical prostate biopsy dataset with undetected cancer"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6852-6605","authenticated-orcid":false,"given":"Eduard","family":"Chelebian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1835-921X","authenticated-orcid":false,"given":"Christophe","family":"Avenel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"J\u00e4remo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernilla","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4139-7003","authenticated-orcid":false,"given":"Carolina","family":"W\u00e4hlby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"4758_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 71, 209\u2013249, https:\/\/doi.org\/10.3322\/caac.21660 (2021).","journal-title":"CA: a cancer journal for clinicians"},{"key":"4758_CR2","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.humpath.2010.02.011","volume":"41","author":"M Andreoiu","year":"2010","unstructured":"Andreoiu, M. & Cheng, L. Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Human pathology 41, 781\u2013793, https:\/\/doi.org\/10.1016\/j.humpath.2010.02.011 (2010).","journal-title":"Human pathology"},{"key":"4758_CR3","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1056\/nejmoa031918","volume":"350","author":"IM Thompson","year":"2004","unstructured":"Thompson, I. M. Prevalence of prostate cancer among men with a prostate-specific antigen level \u2264 4.0 ng per milliliter. New England Journal of Medicine 350, 2239\u20132246, https:\/\/doi.org\/10.1056\/nejmoa031918 (2004).","journal-title":"New England Journal of Medicine"},{"key":"4758_CR4","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1056\/nejmoa0810084","volume":"360","author":"FH Schr\u00f6der","year":"2009","unstructured":"Schr\u00f6der, F. H. Screening and prostate-cancer mortality in a randomized European study. New England journal of medicine 360, 1320\u20131328, https:\/\/doi.org\/10.1056\/nejmoa0810084 (2009).","journal-title":"New England journal of medicine"},{"key":"4758_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.eururo.2020.04.029","volume":"78","author":"JM Norris","year":"2020","unstructured":"Norris, J. M. What type of prostate cancer is systematically overlooked by multiparametric magnetic resonance imaging? An analysis from the PROMIS cohort. European urology 78, 163\u2013170, https:\/\/doi.org\/10.1016\/j.eururo.2020.04.029 (2020).","journal-title":"European urology"},{"key":"4758_CR6","doi-asserted-by":"publisher","first-page":"100633","DOI":"10.1016\/j.phro.2024.100633","volume":"31","author":"J Grefve","year":"2024","unstructured":"Grefve, J. Histopathology-validated gross tumor volume delineations of intraprostatic lesions using PSMA-positron emission tomography\/multiparametric magnetic resonance imaging. Physics and Imaging in Radiation Oncology 31, 100633, https:\/\/doi.org\/10.1016\/j.phro.2024.100633 (2024).","journal-title":"Physics and Imaging in Radiation Oncology"},{"key":"4758_CR7","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.eururo.2007.09.002","volume":"53","author":"A Heidenreich","year":"2008","unstructured":"Heidenreich, A. EAU guidelines on prostate cancer. European urology 53, 68\u201380, https:\/\/doi.org\/10.1016\/j.eururo.2007.09.002 (2008).","journal-title":"European urology"},{"key":"4758_CR8","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1097\/pas.0000000000001497","volume":"44","author":"GeertJLH Van Leenders","year":"2020","unstructured":"Van Leenders, GeertJ. L. H. The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma. The American journal of surgical pathology 44, e87, https:\/\/doi.org\/10.1097\/pas.0000000000001497 (2020).","journal-title":"The American journal of surgical pathology"},{"key":"4758_CR9","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.eururo.2019.12.017","volume":"77","author":"JJ Tosoian","year":"2020","unstructured":"Tosoian, J. J. Active surveillance of grade group 1 prostate cancer: long-term outcomes from a large prospective cohort. European urology 77, 675\u2013682, https:\/\/doi.org\/10.1016\/j.eururo.2019.12.017 (2020).","journal-title":"European urology"},{"key":"4758_CR10","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1016\/j.juro.2013.02.072","volume":"189","author":"MA Bjurlin","year":"2013","unstructured":"Bjurlin, M. A. Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing. The Journal of urology 189, 2039\u20132046, https:\/\/doi.org\/10.1016\/j.juro.2013.02.072 (2013).","journal-title":"The Journal of urology"},{"key":"4758_CR11","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1097\/mnm.0000000000001743","volume":"44","author":"K Sandgren","year":"2023","unstructured":"Sandgren, K. Histopathology-validated lesion detection rates of clinically significant prostate cancer with mpMRI, [68Ga] PSMA-11-PET and [11C] Acetate-PET. Nuclear medicine communications 44, 997\u20131004, https:\/\/doi.org\/10.1097\/mnm.0000000000001743 (2023).","journal-title":"Nuclear medicine communications"},{"key":"4758_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1517\/17530059.2011.540009","volume":"5","author":"S Halin","year":"2011","unstructured":"Halin, S., Hammarsten, P., Adamo, H., Wikstr\u00f6m, P. & Bergh, A. Tumor indicating normal tissue could be a new source of diagnostic and prognostic markers for prostate cancer. Expert opinion on medical diagnostics 5, 37\u201347, https:\/\/doi.org\/10.1517\/17530059.2011.540009 (2011).","journal-title":"Expert opinion on medical diagnostics"},{"key":"4758_CR13","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41591-021-01620-2","volume":"28","author":"W Bulten","year":"2022","unstructured":"Bulten, W. Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge. Nature medicine 28, 154\u2013163, https:\/\/doi.org\/10.1038\/s41591-021-01620-2 (2022).","journal-title":"Nature medicine"},{"key":"4758_CR14","doi-asserted-by":"publisher","unstructured":"Liu, B. et al. Using deep learning to detect patients at risk for prostate cancer despite benign biopsies, Iscience25, https:\/\/doi.org\/10.1016\/j.isci.2022.104663 (2022).","DOI":"10.1016\/j.isci.2022.104663"},{"key":"4758_CR15","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.juro.2014.04.013","volume":"192","author":"AW Partin","year":"2014","unstructured":"Partin, A. W. Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. The Journal of urology 192, 1081\u20131087, https:\/\/doi.org\/10.1016\/j.juro.2014.04.013 (2014).","journal-title":"The Journal of urology"},{"key":"4758_CR16","doi-asserted-by":"publisher","unstructured":"Chelebian, E. et al. Discovery of tumour indicating morphological changes in benign prostate through AI, medRxiv, https:\/\/doi.org\/10.1101\/2024.06.18.24309064 (2024).","DOI":"10.1101\/2024.06.18.24309064"},{"key":"4758_CR17","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41551-020-00682-w","volume":"5","author":"MY Lu","year":"2021","unstructured":"Lu, M. Y. Data-efficient and weakly supervised computational pathology on whole-slide images. Nature biomedical engineering 5, 555\u2013570, https:\/\/doi.org\/10.1038\/s41551-020-00682-w (2021).","journal-title":"Nature biomedical engineering"},{"key":"4758_CR18","doi-asserted-by":"publisher","unstructured":"Chelebian, E., W\u00e4hlby, C. & Bergh, A., Undetected cancer in clinical prostate biopsies, Swedish National Data Service (SND), https:\/\/doi.org\/10.57804\/epa0-8v59 (2024).","DOI":"10.57804\/epa0-8v59"},{"key":"4758_CR19","doi-asserted-by":"publisher","unstructured":"Bankhead, P. et al. QuPath: Open source software for digital pathology image analysis, Scientific reports 7, https:\/\/doi.org\/10.1038\/s41598-017-17204-5 (2017).","DOI":"10.1038\/s41598-017-17204-5"},{"key":"4758_CR20","doi-asserted-by":"publisher","unstructured":"Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis, Nature methods 9, 676\u2013682, https:\/\/doi.org\/10.1038\/nmeth.2019 (2012).","DOI":"10.1038\/nmeth.2019"},{"key":"4758_CR21","doi-asserted-by":"publisher","unstructured":"Pielawski, N. et al. TissUUmaps 3: Improvements in interactive visualization, exploration, and quality assessment of large-scale spatial omics data. Heliyon 9, https:\/\/doi.org\/10.1016\/j.heliyon.2023.e15306 (2023).","DOI":"10.1016\/j.heliyon.2023.e15306"}],"container-title":["Scientific Data"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41597-025-04758-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41597-025-04758-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41597-025-04758-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T10:42:17Z","timestamp":1741862537000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41597-025-04758-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4758"],"URL":"https:\/\/doi.org\/10.1038\/s41597-025-04758-7","relation":{},"ISSN":["2052-4463"],"issn-type":[{"value":"2052-4463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]},"assertion":[{"value":"20 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.W. is on the advisory board of Navinci Diagnostics, Sweden. The rest of the authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"423"}}